特异性抗膀胱癌单克隆抗体对膀胱肿瘤的临床研究

Clinical study of monoclonal antibodies in bladder tumors

采用一组特异性抗膀胱癌单克隆抗体MAb（T16、M344、T138、T43），以APAAP免疫细胞化学方法，对63例膀胱移行细胞癌及10例非肿瘤患者的膀胱冲洗液作了研究。T16在全部63份标本呈阳性。随着肿瘤分期、分级的升高，M344阳性率逐渐降低，T138及T43阳性率逐渐升高。此三种MAb与肿瘤复发也有一定的对应关系。尿细胞学与MAb联合应用，可弥补相互间的不足，使肿瘤检出率进一步提高。结果表明：M344、T138及T43MAb的阳性表达与肿瘤的分期、分级及预后密切相关，可作为膀胱肿瘤恶性程度、复发及早期诊断的估价指标。

Using a panel of four monoclonal antibodies(T16,M344,T138,T43),an mmunocyTochemical(APAAP)study of bladder washings was carried out in 63 cases of transitional Cell carcinoma and 10 of non-tumor patients.The results indicates that the positivity of M344,T138 and T43 was closely related with stage,grade and prognosis.It can be used as Evaluating marker of malignant dergee,recurrence and early diagnosis.